XTL Biopharmaceuticals
XTLB | NASDAQ
$1.54
-$0.06 (-3.75%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
+$0.02 (+1.30%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-3.75%
(1D)No price chart data available for 1D timeframe.
Rating
24.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #949/1021 (Top 93%)
Key Statistics
Market Data
Market Cap $1.46M
1D Range
1.54 1.69
52W Range
1.53 4.28
Valuation (TTM)
PE -0.53
PB -5.74
EV/EBITDA -10.13
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $0.00
Cash Flow
FCF Yield 0.0%
SBC Adj. FCF Yield -18.1%
SBC Impact N/A
Margins
Gross Margin 0.0%
Operating Margin -481.6%
FCF Margin 0.0%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
100.0%
Dil EPS 3Y | 5Y 13.8% |
2.5%
FCF 3Y | 5Y -14.0% |
-6.8%
Returns
ROA -4198.2%
ROE -269.0%
ROIC -11253.3%
Financial Health
Net Debt
$125K
Current Ratio 0.40
Interest Coverage -241.14
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to...
Sector Healthcare
Industry Biotechnology
Employees 10
IPO Date Sep 1, 2005
Website www.xtlbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove XTLB